We present the third prospective assessment for prodromal PD features of a cohort of GBA1 mutation carriers, 4 to 5 years after baseline.10, 11 Our findings suggest that a combination of clinical markers may help define a subgroup of GBA1 mutation carriers at increased risk of PD. The gene discussed is GBA1; the disease is Parkinson disease.